Causality Between Various Cytokines and Asthma: a Bidirectional Two-sample Mendelian Randomization Analysis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Aug 23

PMID 39175819

Authors

Yansen Zheng

Qi Chen

Xiaqing Shi

Lei Lei

Donglin Wang

Affiliations

Soon will be listed here.

Abstract

Background: Many studies have shown that cytokines play an important role in the pathogenesis of asthma, but their biological effects on asthma remain unclear. The Mendelian randomization (MR) method was used to evaluate the causal relationship between various cytokines [such as interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), colony-stimulating factors (CSFs), transforming growth factor (TGF), etc.,] and asthma.

Methods: In this study, inverse variance weighting was used to evaluate the causal relationship between asthma and cytokines. In addition, the reliability of the results is ensured by multiple methods such as MR-Egger, weighted median, MR-Raps, MR-Presso, and RadialMR, as well as sensitivity analysis.

Results: The results showed that none of the 11 cytokines was associated with the risk of asthma. In contrast, asthma can increase levels of IL-5 [odds ratio (OR) = 1.112, 95% confidence interval (CI): 1.009-1.224, = 0.032] and IL-9 (OR = 1.111, 95% CI: 1.013-1.219, = 0.025).

Conclusion: Genetically predicted asthma was positively associated with elevated levels of IL-5 and IL-9, indicating the downstream effects of IL-5 and IL-9 on asthma. Medical treatments can thus be designed to target IL-5 and IL-9 to prevent asthma exacerbations.

References

Shimbara A, Christodoulopoulos P, Olivenstein R, Nakamura Y, Levitt R, Nicolaides N . IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J Allergy Clin Immunol. 2000; 105(1 Pt 1):108-15. DOI: 10.1016/s0091-6749(00)90185-4. View

Kay A, Klion A . Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome. Immunol Allergy Clin North Am. 2004; 24(4):645-66, vii. DOI: 10.1016/j.iac.2004.06.007. View

Dong H, Hao Y, Li W, Yang W, Gao P . IL-36 Cytokines: Their Roles in Asthma and Potential as a Therapeutic. Front Immunol. 2022; 13:921275. PMC: 9314646. DOI: 10.3389/fimmu.2022.921275. View

Fang L, Sun Q, Roth M . Immunologic and Non-Immunologic Mechanisms Leading to Airway Remodeling in Asthma. Int J Mol Sci. 2020; 21(3). PMC: 7037330. DOI: 10.3390/ijms21030757. View

Lu J, Ji X, Wang L, Sun F, Huang C, Peng H . Interleukin‑27 ameliorates allergic asthma by alleviating the lung Th2 inflammatory environment. Int J Mol Med. 2022; 49(6). PMC: 9106376. DOI: 10.3892/ijmm.2022.5142. View

Mahdaviani S, Eskian M, Khorasanizadeh M, Bashardoost B, Tashayoie Nejad S, Jamaati H . Interleukin 9 serum level and single nucleotide polymorphism in patients with asthma. Acta Biomed. 2021; 92(3):e2021206. PMC: 8343737. DOI: 10.23750/abm.v92i3.10544. View

Brooks G, Buchta K, Swenson C, Gern J, Busse W . Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. Am J Respir Crit Care Med. 2003; 168(9):1091-4. DOI: 10.1164/rccm.200306-737OC. View

Ahola-Olli A, Wurtz P, Havulinna A, Aalto K, Pitkanen N, Lehtimaki T . Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet. 2016; 100(1):40-50. PMC: 5223028. DOI: 10.1016/j.ajhg.2016.11.007. View

Gong F, Pan Y, Huang X, Zhu H, Jiang D . From bench to bedside: Therapeutic potential of interleukin-9 in the treatment of asthma. Exp Ther Med. 2017; 13(2):389-394. PMC: 5347659. DOI: 10.3892/etm.2017.4024. View

10.

Stein M, Munitz A . Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases. Recent Pat Inflamm Allergy Drug Discov. 2010; 4(3):201-9. DOI: 10.2174/187221310793564290. View

11.

Hudey S, Ledford D, Cardet J . Mechanisms of non-type 2 asthma. Curr Opin Immunol. 2020; 66:123-128. PMC: 7852882. DOI: 10.1016/j.coi.2020.10.002. View

12.

Waldman I, Robinson B . Meta-analysis of sib pair linkage studies of asthma and the interleukin-9 gene (IL9). Genet Epidemiol. 2002; 21 Suppl 1:S109-14. DOI: 10.1002/gepi.2001.21.s1.s109. View

13.

Neurath M, Finotto S . IL-9 signaling as key driver of chronic inflammation in mucosal immunity. Cytokine Growth Factor Rev. 2016; 29:93-9. DOI: 10.1016/j.cytogfr.2016.02.002. View

14.

Kotsimbos T, Ernst P, Hamid Q . Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc Assoc Am Physicians. 1996; 108(5):368-73. View

15.

Gilly A, Park Y, Png G, Barysenka A, Fischer I, Bjornland T . Whole-genome sequencing analysis of the cardiometabolic proteome. Nat Commun. 2020; 11(1):6336. PMC: 7729872. DOI: 10.1038/s41467-020-20079-2. View

16.

Nur Husna S, Md Shukri N, Mohd Ashari N, Wong K . IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. PeerJ. 2022; 10:e13444. PMC: 9161813. DOI: 10.7717/peerj.13444. View

17.

Louahed J, Toda M, Jen J, Hamid Q, Renauld J, Levitt R . Interleukin-9 upregulates mucus expression in the airways. Am J Respir Cell Mol Biol. 2000; 22(6):649-56. DOI: 10.1165/ajrcmb.22.6.3927. View

18.

Xu L, Liu C, Zheng Y, Huang Y, Zhong Y, Zhao Z . Association of TNF-α-308G/A, -238G/A, -863C/A, -1031T/C, -857C/T polymorphisms with periodontitis susceptibility: Evidence from a meta-analysis of 52 studies. Medicine (Baltimore). 2020; 99(36):e21851. PMC: 7478382. DOI: 10.1097/MD.0000000000021851. View

19.

Kim Y, Kim H, Lee S, Kim S, Lee J, Choi Y . Airway G-CSF identifies neutrophilic inflammation and contributes to asthma progression. Eur Respir J. 2019; 55(2). DOI: 10.1183/13993003.00827-2019. View

20.

Desai D, Brightling C . Cytokine and anti-cytokine therapy in asthma: ready for the clinic?. Clin Exp Immunol. 2009; 158(1):10-9. PMC: 2759053. DOI: 10.1111/j.1365-2249.2009.03998.x. View